View all data FOR FREE!
Create an account today, no credit card required.
| Issue Type | XXXX |
|---|---|
| Country | United States |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2031-11-18 |
| Par Value | 100000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 650.00 |
| Coupon | 1.25 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 650 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Abbvie Inc corporate note has a 1.25% fixed rate coupon paid on a annual basis. It was issued on September 26, 2019 with an issue size of 650.00 million EUR and matures on November 18, 2031 with a last coupon date of November 18, 2030. |
AbbVie Inc, founded in 2013 and headquartered in North Chicago, Illinois, is a global biopharmaceutical company dedicated to the development and commercialization of innovative therapies. The company focuses on various therapeutic areas, including immunology, oncology, neuroscience, and virology, with flagship products such as Humira and Imbruvica contributing significantly to its portfolio.